{"entity":{"id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","aka":["SWIFT 02"],"tldr":"A phase 3 trial of Cyclophosphamide, Doxorubicin, Prednisone and Vincristine in non-Hodgkin lymphoma, run by Chipscreen Biosciences, Ltd., now recruiting.","summary":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype is a phase 3 interventional study registered as NCT06947967 by Chipscreen Biosciences, Ltd., with 224 participants planned, started 2025-08-12 and due to reach its primary completion in 2032-12. Interventions recorded: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06947967","url":"https://clinicaltrials.gov/study/NCT06947967"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","doxorubicin","prednisone","vincristine"],"companies":["chipscreen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06947967","phase":"3","setting":"A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)","sponsor":"Chipscreen Biosciences, Ltd.","participation":[{"nct":"NCT06947967","source":"https://clinicaltrials.gov/study/NCT06947967","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"517906fdf3fb251a0c219d29f142a5fdc837ea09bb7f710934a906ed346ad0d2","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-15","leadSponsor":"Chipscreen Biosciences, Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":224,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-08-12","startedType":"actual","enrolled":224,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06947967/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/"}]}}